WEBULL
WebtradeDownload

Healthpeak Properties (DOC) Stock May Be 44% Below Fair Value

Simply Wall St · 1d ago

Healthpeak Properties has delivered a 34.4% return over the past 3 years, which puts a spotlight on whether the recent share price around US$20.72 is still grounded in the cash the business can generate. For anyone looking at the stock today, the real issue is how that market price lines up with the value implied by Healthpeak Properties' future cash flows.

  • The 34.4% gain over 3 years has meaningfully reshaped investor expectations. The key issue is whether that past share price performance is consistent with the cash the real estate portfolio can produce over time.
  • Healthpeak Properties relies on its rental income and asset base to support cash generation, which can influence how much flexibility it has for reinvestment, debt service and potential shareholder returns.
  • Prefer to judge Healthpeak Properties on earnings? See why Healthpeak Properties's 58.9x P/E tells a different valuation story.

The issue now is whether those cash flows, when discounted through a Discounted Cash Flow (DCF) lens, are enough to justify where Healthpeak Properties trades today.

If you are weighing Healthpeak Properties against other ideas where discounted cash flows matter, a focused starting point is a list of 30 high quality undervalued stocks.

Does Healthpeak Properties Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) approach here uses Healthpeak Properties' adjusted funds from operations to estimate what its future cash generation could be worth today. Latest twelve month free cash flow sits at about $1.29b, which gives you a sense of the scale of cash this real estate owner is working with.

Analysts and internal estimates in the model assume that free cash flow grows gradually over the coming decade rather than swinging sharply, which fits a more mature portfolio of rental assets. On those cash flow paths, the DCF output suggests an intrinsic worth that is substantially above the current share price of $20.72. That gap indicates the market price may not fully reflect the cash flows implied in this model yet. Find out what Healthpeak Properties could be worth using our Discounted Cash Flow (DCF) estimate.

The Healthpeak Properties Narrative: What Would Justify Today's Price?

Healthpeak Properties' Simply Wall St Narratives pick up where the valuation question leaves off by spelling out which paths for growth, margins and earnings would need to play out for the share price to move meaningfully above or below where it trades today. Each scenario is less about a single multiple or model output and more about laying out the assumptions that sit behind its view of fair value, so you can compare those with actual results over time on the Community page.

Community views on Healthpeak Properties split between those who see structural tailwinds supporting the real estate portfolio and those who focus on tenant and balance sheet risk.

Bull case: 10% undervalued

"Supply constraints in key outpatient and life sciences markets are tightening available space, positioning Healthpeak's concentrated, high-quality portfolio to benefit from robust re-leasing spreads..."

Discover why this Narrative puts Healthpeak Properties at 10% undervalued.

Bear case: 15% overvalued

"High tenant risk, market concentration, and ambitious development may create volatility in occupancy, cash flow, and earnings growth..."

Explore why this Narrative puts Healthpeak Properties at 15% overvalued.

Healthpeak Properties valuation is only part of the story

Price and cash flows say a lot about Healthpeak Properties, but the people choosing where capital goes and how they are rewarded can reshape that picture in ways the numbers alone cannot. See who runs Healthpeak Properties and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.